Today Cellevate received approval for a two-year € 2.48 million grant funded through the European Innovation Council Accelerator program. The grant is dedicated to develop and scale up for the large-scale commercialization of the nanofiber-based Cellevat3d™ Microcarriers product portfolio, designed to revolutionize the manufacturing of biological drugs.
Over 1000 companies with innovative products and technologies applied for grants within this program in 2022 with only 7.4% achieving approvals. More information and the full list can be found on the EIC website.
Dr Laura Chirica, CEO, Cellevate, commented: “We are very excited for receiving this very substantial grant and obviously grateful to the European Innovation Council for selecting our project among the many applicants. The funding allows us to accelerate the development and industrial validation of Cellevat3d™ Microcarrier. We believe we can be a very important player in the quest for increasing the efficiency of biopharmaceuticals production as well as biomanufacturing of cell and gene therapy and novel vaccines. The EU grant is a validation and recognition of both Cellevate’s innovative breakthrough nanotechnology, our plans for industrial scale application and of our team.”
Read the original article on Cellevate.
